Triglyceride-rich lipoproteins as agents of innate immunity

Clinical Infectious Diseases

Volumn 41, Issue SUPPL. 7, 2005, Pages

  Barcia, Anthony M ^a   Harris, Hobart W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; CD14 ANTIGEN; CYTOKINE; ENDOTOXIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID A; LIPOPROTEIN; NITRIC OXIDE; PHOSPHOLIPID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL INFECTION; CONFERENCE PAPER; CYTOKINE PRODUCTION; HUMAN; HYPERLIPOPROTEINEMIA; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTOSIS; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

ACUTE-PHASE PROTEINS; ANIMALS; ANTIGENS, CD14; CARRIER PROTEINS; HUMANS; HYPERLIPOPROTEINEMIAS; IMMUNITY, NATURAL; LIPOPOLYSACCHARIDES; LIPOPROTEINS; LIVER; MEMBRANE GLYCOPROTEINS; SEPSIS; TRIGLYCERIDES;

EID: 27744521834     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432005     Document Type: Conference Paper

References (52)

1. Banerjee S, Bhaduri J. Serum protein-bound carbohydrates and lipids in cholera. Proc Soc Exp Biol Med 1959; 101:340-1.
2. Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med 1969; 281:1081-6.
3. Samra JS, Summers LK, Frayn KN. Sepsis and fat metabolism. Br J Surg 1996; 83:1186-96.
4. Wolfe RR, Shaw JH, Durkot MJ. Effect of sepsis on VLDL kinetics: responses in basal state and during glucose infusion. Am J Physiol 1985;248:E732-40.
5. Tripp RJ, Tabares A, Wang H, Lanza-Jacoby S. Altered hepatic production of apolipoproteins B and E in the fasted septic rat: factors in the development of hypertriglyceridemia. J Surg Res 1993; 55:465-72.
6. Harris HW, Eichbaum EB, Kane JP, Rapp JH. Detection of endotoxin in triglyceride-rich lipoproteins in vitro. J Lab Clin Med 1991; 118:186-93.
7. Eichbaum EB, Harris HW, Kane JP, Rapp JH. Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res 1991; 51:413-6.
8. Ulevitch RJ, Johnston AR. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest 1978; 62:1313-24.
9. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins: their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979; 64:1516-24.
10. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins: isolation and characterization of a bacterial lipopolysaccharide- high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67:827-37.
11. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986; 83:2704-8.
12. Navab M, Hough GP, Van Lenten BJ, Berliner JA, Fogelman AM. Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J Clin Invest 1988; 81:601-5.
13. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86:696-702.
14. Cue JI, DiPiro JT, Brunner LJ, et al. Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits. Arch Surg 1994; 129:193-7.
15. Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995; 63:253-8.
16. Rensen PC, Oosten M, Bilt E, Eck M, Kuiper J, Berkel TJ. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest 1997; 99:2438-45.
17. de Bont N, Netea MG, Demacker PN, et al. Apolipoprotein E knockout mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res 1999; 40:680-5.
18. Landmann R, Muller B, Zimmerli W. CD14, new aspects of ligand and signal diversity. Microbes Infect 2000; 2:295-304.
19. Schumann RR, Zweigner J. A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med 1999; 37:271-4.
20. Schutt C. Fighting infection: the role of lipopolysaccharide binding proteins CD14 and LBP. Pathobiology 1999; 67:227-9.
21. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3.
22. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 1988; 141:547-52.
23. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13:437-57.
24. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276:1861-4.
25. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem 1995; 64:235-57.
26. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol 1998; 64:14-8.
27. Bruce C, Beamer LJ, Tall AR. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol 1998; 8:426-34.
28. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein: transfer of LPS to soluble CD14. J Biol Chem 1996; 271:4100-5.
29. Wurfel MM, Wright SD. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. J Immunol 1997; 158:3925-34.
30. Vesy CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from gram-negative bacterial membranes. Infect Immun 2000; 68:2410-7.
31. Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999; 274:34116-22.
32. Hailman E, Lichenstein HS, Wurfel MM, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179:269-77.
33. Netea MG, Demacker PN, Kullberg BJ, et al. Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. Cytokine 1998; 10:766-72.
34. Read TE, Grunfeld C, Kumwenda Z, et al. Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats. Surgery 1995; 117:62-7.
35. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995;63:2041-6.
36. Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23.
37. Casas AT, Hubsch AP, Rogers BC, Doran JE. Reconstituted high-density lipoprotein reduces LPS-stimulated TNF alpha. J Surg Res 1995; 59:544-52.
38. Casas AT, Hubsch AP, Doran JE. Effects of reconstituted high-density lipoprotein in persistent gram-negative bacteremia. Am Surg 1996; 62:350-5.
39. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601-8.
40. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90:12040-4.
41. Harris HW, Rockey DC, Young DM, Welch WJ. Diet-induced protection against lipopolysaccharide includes increased hepatic NO production. J Surg Res 1999; 82:339-45.
42. van der Poll T, Braxton CC, Coyle SM, et al. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun 1995; 63:3396-400.
43. Hajri T, Ferezou J, Lutton C. Effects of intravenous infusions of commercial fat emulsions (Intralipid 10 or 20%) on rat plasma lipoproteins: phospholipids in excess are the main precursors of lipoprotein-X-like particles. Biochim Biophys Acta 1990; 1047:121-30.
44. Ferezou J, Nguyen TL, Leray C, et al. Lipid composition and structure of commercial parenteral emulsions. Biochim Biophys Acta 1994; 1213:149-58.
45. Hultin M, Carneheim C, Rosenqvist K, Olivecrona T. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res 1995;36:2174-84.
46. Abe M, Kawano M, Tashiro T, et al. Catabolism of lipoprotein-X induced by infusion of 10% fat emulsion. Nutrition 1997; 13:417-21.
47. Harris HW, Grunfeld C, Feingold KR, et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91:1028-34.
48. Harris HW, Rockey DC, Chau P. Chylomicrons alter the hepatic distribution and cellular response to endotoxin in rats. Hepatology 1998; 27:1341-8.
49. Harris HW, Johnson JA, Wigmore SJ. Endogenous lipoproteins impact the response to endotoxin in humans. Crit Care Med 2002; 30:23-31.
50. Flegel WA, Wolpl A, Mannel DN, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57:2237-45.
51. Weinstock C, Ullrich H, Hohe R, et al. Low density lipoproteins inhibit endotoxin activation of monocytes. Arterioscler Thromb 1992; 12:341-7.
52. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61:5140-6.